Exemplar Abstract for Bacteroides ovatus Eggerth and Gagnon 1933 (Approved Lists 1980) emend. Hahnke et al. 2016.

2003 ◽  
Author(s):  
Charles Thomas Parker ◽  
Dorothea Taylor ◽  
George M Garrity
Keyword(s):  
2011 ◽  
Vol 56 (3) ◽  
pp. 1247-1252 ◽  
Author(s):  
James A. Karlowsky ◽  
Andrew J. Walkty ◽  
Heather J. Adam ◽  
Melanie R. Baxter ◽  
Daryl J. Hoban ◽  
...  

ABSTRACTClinical isolates of theBacteroides fragilisgroup (n= 387) were collected from patients attending nine Canadian hospitals in 2010-2011 and tested for susceptibility to 10 antimicrobial agents using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method.B. fragilis(59.9%),Bacteroides ovatus(16.3%), andBacteroides thetaiotaomicron(12.7%) accounted for ∼90% of isolates collected. Overall rates of percent susceptibility were as follows: 99.7%, metronidazole; 99.5%, piperacillin-tazobactam; 99.2%, imipenem; 97.7%, ertapenem; 92.0%, doripenem; 87.3%, amoxicillin-clavulanate; 80.9%, tigecycline; 65.9%, cefoxitin; 55.6%, moxifloxacin; and 52.2%, clindamycin. Percent susceptibility to cefoxitin, clindamycin, and moxifloxacin was lowest forB. thetaiotaomicron(n= 49, 24.5%),Parabacteroides distasonis/P. merdae(n= 11, 9.1%), andB. ovatus(n= 63, 31.8%), respectively. One isolate (B. thetaiotaomicron) was resistant to metronidazole, and two isolates (bothB. fragilis) were resistant to both piperacillin-tazobactam and imipenem. Since the last published surveillance study describing Canadian isolates ofB. fragilisgroup almost 20 years ago (A.-M. Bourgault et al., Antimicrob. Agents Chemother. 36:343–347, 1992), rates of resistance have increased for amoxicillin-clavulanate, from 0.8% (1992) to 6.2% (2010-2011), and for clindamycin, from 9% (1992) to 34.1% (2010-2011).


Microbiology ◽  
2008 ◽  
Vol 154 (10) ◽  
pp. 3165-3174 ◽  
Author(s):  
Zaed Z. R. Hamady ◽  
Mark D. Farrar ◽  
Terence R. Whitehead ◽  
Keith T. Holland ◽  
J. Peter A. Lodge ◽  
...  

2018 ◽  
Vol 154 (6) ◽  
pp. S-1036-S-1037
Author(s):  
Faith D. Ihekweazu ◽  
Tatiana Fofanova ◽  
Karen Queliza ◽  
Dorottya Nagy-Szakal ◽  
Christopher Stewart ◽  
...  

Biochimie ◽  
2012 ◽  
Vol 94 (1) ◽  
pp. 222-230 ◽  
Author(s):  
Agustín Sola-Carvajal ◽  
Guiomar Sánchez-Carrón ◽  
María Inmaculada García-García ◽  
Francisco García-Carmona ◽  
Álvaro Sánchez-Ferrer
Keyword(s):  

Open Biology ◽  
2016 ◽  
Vol 6 (7) ◽  
pp. 160142 ◽  
Author(s):  
Glyn R. Hemsworth ◽  
Andrew J. Thompson ◽  
Judith Stepper ◽  
Łukasz F. Sobala ◽  
Travis Coyle ◽  
...  

The human gastrointestinal tract harbours myriad bacterial species, collectively termed the microbiota, that strongly influence human health. Symbiotic members of our microbiota play a pivotal role in the digestion of complex carbohydrates that are otherwise recalcitrant to assimilation. Indeed, the intrinsic human polysaccharide-degrading enzyme repertoire is limited to various starch-based substrates; more complex polysaccharides demand microbial degradation. Select Bacteroidetes are responsible for the degradation of the ubiquitous vegetable xyloglucans (XyGs), through the concerted action of cohorts of enzymes and glycan-binding proteins encoded by specific xyloglucan utilization loci (XyGULs). Extending recent (meta)genomic, transcriptomic and biochemical analyses, significant questions remain regarding the structural biology of the molecular machinery required for XyG saccharification. Here, we reveal the three-dimensional structures of an α-xylosidase, a β-glucosidase, and two α- l -arabinofuranosidases from the Bacteroides ovatus XyGUL. Aided by bespoke ligand synthesis, our analyses highlight key adaptations in these enzymes that confer individual specificity for xyloglucan side chains and dictate concerted, stepwise disassembly of xyloglucan oligosaccharides. In harness with our recent structural characterization of the vanguard endo-xyloglucanse and cell-surface glycan-binding proteins, the present analysis provides a near-complete structural view of xyloglucan recognition and catalysis by XyGUL proteins.


2020 ◽  
Vol 27 (3) ◽  
pp. 467-475.e6 ◽  
Author(s):  
Chao Yang ◽  
Ilaria Mogno ◽  
Eduardo J. Contijoch ◽  
Joshua N. Borgerding ◽  
Varun Aggarwala ◽  
...  

2019 ◽  
Vol 76 (21) ◽  
pp. 4319-4340 ◽  
Author(s):  
Kazune Tamura ◽  
Matthew H. Foley ◽  
Bernd R. Gardill ◽  
Guillaume Dejean ◽  
Matthew Schnizlein ◽  
...  

1997 ◽  
Vol 41 (5) ◽  
pp. 1037-1041 ◽  
Author(s):  
L M Ednie ◽  
S K Spangler ◽  
M R Jacobs ◽  
P C Appelbaum

Agar dilution methodology (with added Oxyrase in the case of the macrolide group to allow incubation without added CO2) was used to compare the activity of RU 64004, a new ketolide, with the activities of erythromycin, azithromycin, clarithromycin, roxithromycin, clindamycin, amoxicillin with and without clavulanate, piperacillin with and without tazobactam, metronidazole, and imipenem against 379 anaerobes. Overall, RU 64004 yielded an MIC at which 50% of the isolates are inhibited (MIC50) of 1.0 microg/ml and an MIC90 of 16.0 microg/ml. In comparison, MIC50s and MIC90s of erythromycin, azithromycin, clarithromycin, and roxithromycin were 2.0 to 8.0 and >64.0 microg/ml, respectively. MICs of macrolides, including RU 64004, were higher for Bacteroides ovatus, Fusobacterium varium, Fusobacterium mortiferum, and Clostridium difficile than for the other species. RU 64004 was more active against gram-positive rods and cocci, Prevotella and Porphyromonas spp., and fusobacteria other than F. mortiferum and F. varium than against the Bacteroides fragilis group. Overall MIC50s and MIC90s (in micrograms per milliliter), respectively, of other compounds were as follows: clindamycin, 1.0 and 16.0; amoxicillin, 4.0 and 64.0; amoxicillin-clavulanate, 0.5 and 4.0; piperacillin, 8.0 and >64.0; piperacillin-tazobactam, 1.0 and 16.0; metronidazole, 1.0 and 4.0; and imipenem, 0.25 and 1.0.


2016 ◽  
Vol 4 (6) ◽  
Author(s):  
Udo Wegmann ◽  
Alexander Goesmann ◽  
Simon R. Carding

The complete genome sequence ofBacteroides ovatusV975 was determined. The genome consists of a single circular chromosome of 6,475,296 bp containing five rRNA operons, 68 tRNA genes, and 4,959 coding genes.


Sign in / Sign up

Export Citation Format

Share Document